Rosetta Genomics mesothelioma test licensed to Prometheus Labs
Rosetta Genomics announced earlier this year that its microRNA-based mesothelioma test, miRview™ meso, was being produced in the company’s labs in Philadelphia, Pennsylvania and was available to physicians. See related story. The test represented a significant step forward in allowing physicians to easily and definitively distinguish between pleural mesothelioma and lung cancer. Both cancers are caused by asbestos exposure, but pleural mesothelioma attacks the membrane that surrounds the lungs (the “pleura”) rather than the lung tissue itself.
On April 30th, Rossetta Genomics announced the closing of license and collaboration arrangements with Prometheus Labs. Prometheus also closed its purchase of 2 million shares of Rosetta stock at $4.00 per share. Along with the rights to produce the mesothelioma test developed by Rosetta Genomics, Prometheus will have the rights to two other microRNA-based cancer diagnostic tests: miRview™ mets and miRview™ squamous.
For the full story, go to Rosetta Genomics’ Press Release.
